A detailed history of Black Rock Inc. transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,208,337 shares of TBPH stock, worth $35.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,208,337
Previous 4,587,834 8.27%
Holding current value
$35.7 Million
Previous $51.6 Million 26.8%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$8.22 - $11.59 $3.12 Million - $4.4 Million
-379,497 Reduced 8.27%
4,208,337 $37.7 Million
Q4 2023

Feb 13, 2024

BUY
$8.58 - $11.4 $179,356 - $238,305
20,904 Added 0.46%
4,587,834 $51.6 Million
Q3 2023

Nov 13, 2023

SELL
$8.38 - $10.44 $4.31 Million - $5.37 Million
-514,285 Reduced 10.12%
4,566,930 $39.4 Million
Q2 2023

Aug 11, 2023

SELL
$10.16 - $11.92 $624,453 - $732,627
-61,462 Reduced 1.2%
5,081,215 $52.6 Million
Q1 2023

May 12, 2023

SELL
$9.87 - $11.44 $1.86 Million - $2.15 Million
-188,100 Reduced 3.53%
5,142,677 $55.8 Million
Q4 2022

Feb 13, 2023

BUY
$9.65 - $11.34 $2.15 Million - $2.53 Million
223,250 Added 4.37%
5,330,777 $59.8 Million
Q3 2022

Nov 14, 2022

BUY
$8.39 - $10.22 $711,362 - $866,523
84,787 Added 1.69%
5,107,527 $51.8 Million
Q2 2022

Aug 12, 2022

BUY
$8.41 - $10.34 $787,176 - $967,824
93,600 Added 1.9%
5,022,740 $45.5 Million
Q1 2022

May 12, 2022

SELL
$8.33 - $12.96 $609,947 - $948,970
-73,223 Reduced 1.46%
4,929,140 $47.1 Million
Q4 2021

Feb 10, 2022

SELL
$7.42 - $11.05 $757,552 - $1.13 Million
-102,096 Reduced 2.0%
5,002,363 $55.3 Million
Q3 2021

Nov 09, 2021

BUY
$6.77 - $14.41 $3.95 Million - $8.41 Million
583,752 Added 12.91%
5,104,459 $37.8 Million
Q2 2021

Aug 11, 2021

BUY
$14.52 - $22.46 $65.6 Million - $102 Million
4,520,707 New
4,520,707 $65.6 Million

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $566M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.